Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Sponsor
Sun Yat-sen University
Study ID
NCT04548271
Phase
PHASE2
Status
Unknown

Conditions

  • Nasopharyngeal Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Anti-PD-1 targeted immunotherapy
  • Apatinib — DRUG
    A small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor

Study Details

The purpose of this study is to explore the efficacy and safety of combination of Apatinib and Camrelizumab regimen in treating recurrent or metastatic nasopharyngeal carcinoma patients who were resistant to PD-1 antagonists.

Key Dates

Start date
Sep 30, 2020
Status verified
Sep 2020
Primary completion
Oct 31, 2022
Completion
Oct 31, 2023

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab+Apatinib
    Patients with recurrent or metastatic nasopharyngeal carcinoma who failed to first-line platinum-based chemotherapy and had prior treatment with PD-1 antagonists. Every patients will receive apatinib 250mg orally every day starting 14 days prior to Camrelizumab. Then apatinib 250mg orally every day and Camrelizumab 200mg iv every 3 weeks until disease progression or intolerance of side effects.

Primary Outcome Measure

Objective response rate [ Time Frame: 2 years ]

Central Contacts

Related Studies